Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis — AI Research | MarketCI

SUPN

Market Closed

Supernus Pharmaceuticals, Inc.

NASDAQHealthcare Drug Manufacturers - Specialty & Generic

778 employees

CEO: Jack A. Khattar

Founded: 2012

$48.04

+$0.00(+NaN%)

Market Cap

2.79B

Beta

0.54

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

SUPN Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for SUPN built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Hold

Pass %

57.14%

Score

4/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$114.94

AI Price Target

Machine learning • Price prediction

$46.81

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$0.00

Financial Health

Bankruptcy risk assessment

4.87

Quality Score

Financial strength rating

3.00

AI Investment Grade

Deep analysis of filings & news

65.00

Key Investment Highlights

Important factors affecting SUPN investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

44.74% Poor

Conditions Met

17.00/38.00

Due Diligence Score

44.74%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Fail
	Fail
	Fail
	Fail
	Fail

Showing 1 to 6 of 46 conditions